Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Epistaxis, Blood Pressure
Interventions
Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
Interventions
Pazopanib, Placebo oral capsule
Drug
Lead sponsor
Cure HHT
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Postoperative Pain
Interventions
RADA16 hydrogel
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Livingston, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Epistaxis
Interventions
Tranexamic Acid, 0.9% Sodium Chloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Epistaxis, Hereditary Hemorrhagic Telangiectasia
Interventions
Sclerotherapy, Standard Treatment
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced May 21, 2026, 8:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
Conditions
Nasotracheal Intubation, Nasal Bleeding
Interventions
Nasotracheal intubation over a bougie, Conventional Nasotracheal Intubation
Procedure
Lead sponsor
University of Iowa
Other
Eligibility
8 Years to 99 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Epistaxis
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced May 21, 2026, 8:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers
Conditions
Epistaxis Nosebleed
Interventions
Nasal Compression Device, Routine Care
Device · Diagnostic Test
Lead sponsor
NasaClip
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
Interventions
Sterile saline, Bevacizumab, Estriol, Tranexamic Acid
Drug
Lead sponsor
James Gossage
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Epistaxis
Interventions
Parker flex-tip nasotracheal tube, Standard nasotracheal tube
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years to 11 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
ALN-6400, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Cypress, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Timolol Gel, Placebo Gel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Submucosal Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced May 21, 2026, 8:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
Conditions
Epistaxis
Interventions
2009-I-Epistaxis-1
Device
Lead sponsor
HemCon Medical Technologies, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Epistaxis
Interventions
Tranexamic Acid, Placebo
Drug · Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Boardman, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced May 21, 2026, 8:43 PM EDT
Completed Phase 4 Interventional Results available
Conditions
HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
Interventions
Bevacizumab, Placebo (Saline)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Nasal Obstruction, Rhinitis, Vasomotor, Epistaxis
Interventions
Saline mixture
Other
Lead sponsor
Lisa Shnayder
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
TER-1754, Placebo
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pomalidomide Oral Product, Placebo oral capsule
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Epistaxis
Interventions
Thrombin-JMI, Merocel pack
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced May 21, 2026, 8:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
Conditions
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
Interventions
Not listed
Lead sponsor
Cure HHT
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced May 21, 2026, 8:43 PM EDT
Conditions
Epistaxis
Interventions
Microporous Polysaccharide Hemospheres, Nasal Tampon
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced May 21, 2026, 8:43 PM EDT